FreeTheAI

Zealand Pharma Partners With Generate Biomedicines for AI Obesity Drugs

NeutralMedium impact
ZEALDKK 231.30 −1.49%

Zealand Pharma A/S (OMXCOP:ZEAL) has partnered with Generate Biomedicines to develop artificial intelligence-engineered protein treatments for obesity and metabolic disorders. Under the agreement, Generate Biomedicines receives an initial payment of $30 million, alongside up to $35 million in potential early research milestones. The overall deal could reach approximately $1.2 billion in total milestone payments, plus tiered royalties on future sales. Shares of Zealand Pharma A/S traded down 1.49% to 231.3 DKK following the announcement.

The partnership allows Zealand Pharma A/S to broaden its research pipeline beyond its primary focus on peptides into AI-designed protein therapeutics. Zealand Pharma A/S will maintain operational control over clinical development and commercialization, while Generate Biomedicines provides the underlying drug design technology.

Looking ahead, investors will watch for progress in early preclinical testing. Key future developments include candidate selection, investigational new drug filings, and early clinical data that could trigger larger milestone obligations.

Key points

  • Zealand Pharma A/S signed a deal with Generate Biomedicines to develop AI-designed protein drugs for obesity and metabolic diseases.
  • Generate Biomedicines receives $30 million upfront and up to $35 million in early preclinical milestone payments.
  • Total milestones under the agreement could reach approximately $1.2 billion, alongside tiered royalty rights for Generate Biomedicines.
  • Zealand Pharma A/S will retain leadership and control over downstream clinical trials and potential commercialization.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the deal between Zealand Pharma and Generate Biomedicines?

Zealand Pharma and Generate Biomedicines agreed to collaborate on designing AI-engineered protein therapeutics for obesity and metabolic diseases.

How much is the Zealand Pharma deal worth to Generate Biomedicines?

Generate Biomedicines receives $30 million upfront, up to $35 million in early preclinical milestones, and is eligible for up to ~$1.2 billion in total milestones plus tiered royalties.

Who will manage clinical trials and commercialization for the partnership?

Zealand Pharma will lead all clinical development and potential commercialization efforts for candidates developed under the collaboration.